Cargando…
Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation
Targeting oxidative phosphorylation (OXPHOS) is a promising strategy to improve treatment outcomes of acute myeloid leukemia (AML) patients. IACS-010759 is a mitochondrial complex I inhibitor that has demonstrated preclinical antileukemic activity and is being tested in Phase I clinical trials. Howe...
Autores principales: | Liu, Fangbing, Kalpage, Hasini A., Wang, Deying, Edwards, Holly, Hüttemann, Maik, Ma, Jun, Su, Yongwei, Carter, Jenna, Li, Xinyu, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Wang, Guan, Taub, Jeffrey W., Ge, Yubin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564145/ https://www.ncbi.nlm.nih.gov/pubmed/32847115 http://dx.doi.org/10.3390/cancers12092400 |
Ejemplares similares
-
Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
por: Li, Xinyu, et al.
Publicado: (2019) -
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
por: Qiao, Xinan, et al.
Publicado: (2021) -
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
por: Li, Xinyu, et al.
Publicado: (2020) -
Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia
por: Luedtke, Daniel A., et al.
Publicado: (2020) -
Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia
por: Wang, Tingting, et al.
Publicado: (2019)